机构:
Bayer PLC, Med Affairs Stat, 400 South Oak Way, Reading, Berks, England
UCL, Dept Stat Sci, 1-19 Torrington Pl, London, EnglandBayer PLC, Med Affairs Stat, 400 South Oak Way, Reading, Berks, England
Remiro-Azocar, Antonio
[1
,2
]
机构:
[1] Bayer PLC, Med Affairs Stat, 400 South Oak Way, Reading, Berks, England
[2] UCL, Dept Stat Sci, 1-19 Torrington Pl, London, England
Background Anchored covariate-adjusted indirect comparisons inform reimbursement decisions where there are no head-to-head trials between the treatments of interest, there is a common comparator arm shared by the studies, and there are patient-level data limitations. Matching-adjusted indirect comparison (MAIC), based on propensity score weighting, is the most widely used covariate-adjusted indirect comparison method in health technology assessment. MAIC has poor precision and is inefficient when the effective sample size after weighting is small. Methods A modular extension to MAIC, termed two-stage matching-adjusted indirect comparison (2SMAIC), is proposed. This uses two parametric models. One estimates the treatment assignment mechanism in the study with individual patient data (IPD), the other estimates the trial assignment mechanism. The first model produces inverse probability weights that are combined with the odds weights produced by the second model. The resulting weights seek to balance covariates between treatment arms and across studies. A simulation study provides proof-of-principle in an indirect comparison performed across two randomized trials. Nevertheless, 2SMAIC can be applied in situations where the IPD trial is observational, by including potential confounders in the treatment assignment model. The simulation study also explores the use of weight truncation in combination with MAIC for the first time. Results Despite enforcing randomization and knowing the true treatment assignment mechanism in the IPD trial, 2SMAIC yields improved precision and efficiency with respect to MAIC in all scenarios, while maintaining similarly low levels of bias. The two-stage approach is effective when sample sizes in the IPD trial are low, as it controls for chance imbalances in prognostic baseline covariates between study arms. It is not as effective when overlap between the trials' target populations is poor and the extremity of the weights is high. In these scenarios, truncation leads to substantial precision and efficiency gains but induces considerable bias. The combination of a two-stage approach with truncation produces the highest precision and efficiency improvements. Conclusions Two-stage approaches to MAIC can increase precision and efficiency with respect to the standard approach by adjusting for empirical imbalances in prognostic covariates in the IPD trial. Further modules could be incorporated for additional variance reduction or to account for missingness and non-compliance in the IPD trial.
机构:
Univ Toronto, Princess Margaret Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada
Princess Margaret Hosp, Med Oncol & Hematol, 610 Univ Ave, Toronto, ON M5G2M9, CanadaUniv Toronto, Princess Margaret Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada
Gupta, Vikas
Mascarenhas, John
论文数: 0引用数: 0
h-index: 0
机构:
Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USAUniv Toronto, Princess Margaret Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada
Mascarenhas, John
Kremyanskaya, Marina
论文数: 0引用数: 0
h-index: 0
机构:
Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USAUniv Toronto, Princess Margaret Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada
Kremyanskaya, Marina
Rampal, Raajit K.
论文数: 0引用数: 0
h-index: 0
机构:
Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY USAUniv Toronto, Princess Margaret Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada
Rampal, Raajit K.
Talpaz, Moshe
论文数: 0引用数: 0
h-index: 0
机构:
Univ Michigan, Hematol Clin, Comprehens Canc Ctr, Ann Arbor, MI USAUniv Toronto, Princess Margaret Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada
Talpaz, Moshe
Kiladjian, Jean-Jacques
论文数: 0引用数: 0
h-index: 0
机构:
Univ Paris, Hop St Louis, Clin Invest Ctr, Paris, FranceUniv Toronto, Princess Margaret Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada
Kiladjian, Jean-Jacques
Vannucchi, Alessandro M.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Florence, Azienda Osped Univ Careggi, Dept Hematol, Florence, ItalyUniv Toronto, Princess Margaret Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada
Vannucchi, Alessandro M.
Verstovsek, Srdan
论文数: 0引用数: 0
h-index: 0
机构:
Univ Texas MD Anderson Canc Ctr, Leukemia Dept, Houston, TX USAUniv Toronto, Princess Margaret Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada
Verstovsek, Srdan
Colak, Gozde
论文数: 0引用数: 0
h-index: 0
机构:
MorphoSys Co, Constellat Pharmaceut Inc, Boston, MA USAUniv Toronto, Princess Margaret Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada
Colak, Gozde
Dey, Debarshi
论文数: 0引用数: 0
h-index: 0
机构:
MorphoSys AG, Planegg, GermanyUniv Toronto, Princess Margaret Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada
Dey, Debarshi
Harrison, Claire
论文数: 0引用数: 0
h-index: 0
机构:
Guys & St Thomas Natl Hlth Serv Fdn Trust, Dept Haematol, London, EnglandUniv Toronto, Princess Margaret Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada
机构:
Univ Washington, Swedish Med Ctr, Seattle, WA USA
Univ Washington, Providence St Joseph Hlth, Seattle, WA USAUniv Washington, Swedish Med Ctr, Seattle, WA USA
Mease, P. J.
Warren, R. B.
论文数: 0引用数: 0
h-index: 0
机构:
Northern Care Alliance NHS Fdn Trust, Dermatol Ctr, Manchester, Lancs, EnglandUniv Washington, Swedish Med Ctr, Seattle, WA USA
Warren, R. B.
Nash, P.
论文数: 0引用数: 0
h-index: 0
机构:
Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, NIHR Manchester Biomed Res Ctr, Manchester, Lancs, EnglandUniv Washington, Swedish Med Ctr, Seattle, WA USA
Nash, P.
Grouin, J. M.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Rouin, Rouen, Normandy, FranceUniv Washington, Swedish Med Ctr, Seattle, WA USA
Grouin, J. M.
Willems, D.
论文数: 0引用数: 0
h-index: 0
机构:
UCB Pharma, Brussels, BelgiumUniv Washington, Swedish Med Ctr, Seattle, WA USA
Willems, D.
Taieb, V
论文数: 0引用数: 0
h-index: 0
机构:
UCB Pharma, Colombes, FranceUniv Washington, Swedish Med Ctr, Seattle, WA USA
Taieb, V
Eells, J.
论文数: 0引用数: 0
h-index: 0
机构:
UCB Pharma, Slough, Berks, EnglandUniv Washington, Swedish Med Ctr, Seattle, WA USA
Eells, J.
McInnes, I.
论文数: 0引用数: 0
h-index: 0
机构:
Glasgow Biomed Res Ctr, Glasgow, Lanark, ScotlandUniv Washington, Swedish Med Ctr, Seattle, WA USA
机构:
Hosp Univ 12 Octubre, Dept Med Oncol, Edif Maternidad,2a Planta Av Cordoba S-N, Madrid 28041, SpainHosp Univ 12 Octubre, Dept Med Oncol, Edif Maternidad,2a Planta Av Cordoba S-N, Madrid 28041, Spain
Castro, Elena
Wang, Di
论文数: 0引用数: 0
h-index: 0
机构:
EVERSANATM, Value & Evidence, Burlington, ON, CanadaHosp Univ 12 Octubre, Dept Med Oncol, Edif Maternidad,2a Planta Av Cordoba S-N, Madrid 28041, Spain
Wang, Di
Walsh, Sarah
论文数: 0引用数: 0
h-index: 0
机构:
EVERSANATM, Value & Evidence, Burlington, ON, CanadaHosp Univ 12 Octubre, Dept Med Oncol, Edif Maternidad,2a Planta Av Cordoba S-N, Madrid 28041, Spain
Walsh, Sarah
Craigie, Samantha
论文数: 0引用数: 0
h-index: 0
机构:
EVERSANATM, Value & Evidence, Burlington, ON, CanadaHosp Univ 12 Octubre, Dept Med Oncol, Edif Maternidad,2a Planta Av Cordoba S-N, Madrid 28041, Spain
Craigie, Samantha
Haltner, Anja
论文数: 0引用数: 0
h-index: 0
机构:
EVERSANATM, Value & Evidence, New York, NY USAHosp Univ 12 Octubre, Dept Med Oncol, Edif Maternidad,2a Planta Av Cordoba S-N, Madrid 28041, Spain
Haltner, Anja
Nazari, Jonathan
论文数: 0引用数: 0
h-index: 0
机构:
Pfizer Inc, Global Value & Evidence Oncol, New York, NY USAHosp Univ 12 Octubre, Dept Med Oncol, Edif Maternidad,2a Planta Av Cordoba S-N, Madrid 28041, Spain
Nazari, Jonathan
Niyazov, Alexander
论文数: 0引用数: 0
h-index: 0
机构:
Pfizer Inc, Global Value & Evidence Oncol, New York, NY USAHosp Univ 12 Octubre, Dept Med Oncol, Edif Maternidad,2a Planta Av Cordoba S-N, Madrid 28041, Spain
Niyazov, Alexander
Samjoo, Imtiaz A.
论文数: 0引用数: 0
h-index: 0
机构:
EVERSANATM, Value & Evidence, Burlington, ON, CanadaHosp Univ 12 Octubre, Dept Med Oncol, Edif Maternidad,2a Planta Av Cordoba S-N, Madrid 28041, Spain